Citi Raises Keymed Bio's Target Price to HK$97.5, Maintains Buy/High-Risk Rating

Stock News08-21

Citi has released a research report highlighting that KEYMED BIO-B (02162) posted first-half 2026 revenue of RMB617 million, marking a 24% year-over-year increase. Notably, sales of stapokibart reached RMB393 million, surging 132% compared to the same period last year.

Management has lifted its full-year 2026 sales guidance for stapokibart from RMB750 million to RMB850 million, while reiterating a peak sales target exceeding RMB5 billion. The firm believes the market potential for stapokibart, CMG901, and CM512 has yet to be fully reflected in the current share price.

Consequently, Citi has raised its target price for the company from HK$85 to HK$97.5, while keeping a "Buy/High-Risk" rating intact.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment